GLP-1
Treatment Review
← Peptide library

The evidence reference

Retatrutide

LY3437943

Investigational

Sources checked 2026-10-27

Reading this profile

When a summary centers on an average, look for the information surrounding it. Check whether the report describes the spread of results, uncertainty around the estimate, and the participants included in the calculation. If results are shown at several time points, keep each estimate attached to its observation period. A prominent average should not become a promise about a particular person. Equally, uncertainty should remain a description of what the estimate leaves unresolved. Build the reading note around what the report supports at the group level and what would require a different kind of evidence.

Formulation and route

Studied as a subcutaneous injection.

Mechanism

Activates GIP, GLP-1 and glucagon receptors.

Research evidence

A randomized obesity trial was funded by Lilly.

Limits of the evidence

Trial averages do not predict an individual outcome.

Safety context

The trial reported gastrointestinal adverse events.

Questions to take further

  1. What does the report show about variation around the headline average?
  2. Which participants and observation period contribute to the displayed estimate?
  3. Where does the wording shift from a group result to an individual promise?

Original sources

  1. FDA GLP-1FDA · Checked 2026-10-27
  2. JastreboffPubMed · Checked 2026-10-27

Continue your research

An educational reference from the Comparison Desk. AI-assisted; not reviewed by a licensed clinician. This library does not provide prescriptions or instructions for self-treatment.